Myelofibrosis (MF) is a rare blood cancer that causes various symptoms like anemia, tiredness, enlarged spleen, and low red blood cells. In a pivotal development for MF patients, the European Medicines Agency (EMA) has given the green light to momelotinib (Omjjara), a targeted therapy offering hope and progress in the ones affected by this rare blood disorder.
GSK today announced it and Omjjara is the first authorized medicine in the EU for disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anemia who have primary myelofibrosis, post polycythemia vera myelofibrosis or post essential thrombocythemia myelofibrosis and who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Nina Mojas, Senior Vice President, Oncology Global Product Strategy, GSK, said:
“The challenges of living with myelofibrosis can be burdensome, and symptomatic patients can experience spleen enlargement, fatigue, night sweats and bone pain. Until now, there have been no options specifically indicated to treat these symptoms in patients who also experience anemia. The authorisation of Omjjara brings a new treatment option with a differentiated mechanism of action to these patients in the EU.”
Check out the official press release to delve into the details of momelotinib's approval and gain comprehensive insights into this groundbreaking development.
Join the Global MPN Scientific Foundation!
Stay tuned next week as we bring you further updates and exciting developments on this significant milestone. We invite you to join our community, stay informed, and be a part of this empowering journey towards improved Myelofibrosis treatment. Your engagement and support are crucial in driving progress and finding hope within the MPN community!
Comments